Skip to main content

Featured

Ottawa Wants to Raise Your Deposit Insurance to $250,000: What Changes (and What Doesn’t)

  For more than 20 years, the federal guarantee on your savings has been stuck at $100,000. In Thursday's budget, Ottawa proposed to raise it to $250,000. Here is what would change, what wouldn't, and why you shouldn't move a dollar yet. Today (unchanged since 2005) $100,000 per deposit category Proposed in Budget 2026 $250,000 per deposit category What Budget 2026 actually proposes The Canada Deposit Insurance Corporation (CDIC) protects your deposits if a member bank fails. The budget proposes amendments to the CDIC Act that would do four things: Raise the limit from $100,000 to $250,000 per deposit category, the first increase in more than two decades. Remove the limit entirely for eligible deposits held in registered and tax-free accounts. Today, the limit is $100,000 per account type at each institution. Add temporary high-balance coverage for life events such as selling a home. Require a review of the deposit insurance framework every 10 years. It isn't law yet. ...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment